<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03017352</url>
  </required_header>
  <id_info>
    <org_study_id>Eudract-nr.: 2016-001365-92</org_study_id>
    <nct_id>NCT03017352</nct_id>
  </id_info>
  <brief_title>Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetic Cases</brief_title>
  <acronym>MAG1C</acronym>
  <official_title>Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetic Cases: A Randomised, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Filip Krag Knop</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Steno Diabetes Center Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with type 1 diabetes (T1D) depend on insulin therapy as substitution for the lack of&#xD;
      endocrine insulin production due to an autoimmune destruction of beta-cells in the pancreatic&#xD;
      inslets. Insulin therapy is based on long lasting basal insulin for controlling fasting&#xD;
      plasma glucose, and short lasting mealtime insulin for the postprandial plasma glucose. The&#xD;
      long term efficacy of this treatment is measured in glycated haemoglobin A1c (HbA1c) of &lt;7.0%&#xD;
      as the treatment goal.&#xD;
&#xD;
      Intensive insulin therapy is associated with side effects such as hypoglycaemia, weight gain,&#xD;
      and unwanted exaggerated excursions in PPG. This may ultimately affect treatment compliance.&#xD;
&#xD;
      The abovementioned problems associated with insulin treatment in T1D can also be seen in&#xD;
      insulin-treated patients with type 2 diabetes (T2D). However, in T2D the combination of&#xD;
      insulin with glucagon-like peptide-1 (GLP-1) receptor agonist (RA) has proven effective in&#xD;
      reducing the weight gain and insulin dose in insulin-treated patients with T2D without&#xD;
      exacerbating the risk of hypoglycaemia.&#xD;
&#xD;
      Exenatid is a short lasting GLP-1RA approved for treatment in T2D, and the investigators&#xD;
      intend to evaluate it in a randomized, controlled trial as add-on therapy to standard insulin&#xD;
      therapy for patients with T1D.&#xD;
&#xD;
      The investigators hypothesise that the add-on of exenatide to insulin therapy in patients&#xD;
      with T1D will reduce insulin requirements, glycaemic excursions and body weight and improve&#xD;
      glycaemic control without increasing the risk of hypoglycaemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Actual">June 2019</completion_date>
  <primary_completion_date type="Actual">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>6 months</time_frame>
    <description>Change in HbA1c from baseline to end of study (time 6 months)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events (including hypoglycaemic episodes)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in insulin dosage</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in body weight</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in BMI</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in body composition</measure>
    <time_frame>6 months</time_frame>
    <description>DXA scan measuring bonemineral density</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in body composition</measure>
    <time_frame>6 months</time_frame>
    <description>DXA scan measuring lean mass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in body composition</measure>
    <time_frame>6 months</time_frame>
    <description>DXA scan measuring fat mass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in fasting plasma glucose</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in post prandial plasma glucose</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in fasting plasma levels of C-peptide</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life self reported</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of Life Questionaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment satisfaction</measure>
    <time_frame>6 months</time_frame>
    <description>Diabetes treatment satisfactory questionnaire status version</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment satisfaction</measure>
    <time_frame>6 months</time_frame>
    <description>Diabetes treatment satisfactory questionnaire change version</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dietary patterns</measure>
    <time_frame>6 months</time_frame>
    <description>Food frequency questionaire three times during the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL (High Density Lipoprotein)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL (Low Density Lipoprotein)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VLDL (Very Low Density Lipoprotein)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total cholesterol</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>triglycerides</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proBNP (Pro-Brain Natriuretic Peptide)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hsCRP (High-Sensitivity C-Reactive Protein)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exenatide 10 mikrogram, thrice daily, subcutaneous injection prior to main meals, 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, thrice daily, subcutaneous injection prior to main meals, 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Byetta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  T1D according to WHO criteria with duration of ≥1 year&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  BMI &gt;22.0 kg/m2&#xD;
&#xD;
          -  HbA1c &gt;7.5% and &lt;10.0% at visit 0 (screening)&#xD;
&#xD;
          -  Able to count carbohydrates&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Insulin pump treatment&#xD;
&#xD;
          -  Hypoglycaemia unawareness (inability to register low blood glucose)&#xD;
&#xD;
          -  Diabetic gastroparesis&#xD;
&#xD;
          -  Compromised kidney function (eGFR &lt;60 ml/min/1.73m2, dialysis or kidney&#xD;
             transplantation)&#xD;
&#xD;
          -  Liver disease with elevated plasma alanine aminotransferase (ALT) &gt; three times the&#xD;
             upper limit of normal (measured at visit 0 with the possibility of one repeat analysis&#xD;
             within a week, and the last measured value as being conclusive)&#xD;
&#xD;
          -  History of acute and/or chronic pancreatitis&#xD;
&#xD;
          -  Subjects with personal or family history of medullary carcinoma or MEN syndrome&#xD;
&#xD;
          -  Inflammatory bowel disease&#xD;
&#xD;
          -  Cancer unless in complete remission for &gt;5 years&#xD;
&#xD;
          -  Proliferative retinopathy&#xD;
&#xD;
          -  Other concomitant disease or treatment that according to the investigator's assessment&#xD;
             makes the patient unsuitable for study participation&#xD;
&#xD;
          -  Alcohol/drug abuse&#xD;
&#xD;
          -  Fertile women not using chemical (tablet/pill, depot injection of progesterone,&#xD;
             subdermal gestagen implantation, hormonal vaginal ring or transdermal hormonal patch)&#xD;
             or mechanical (spirals) contraceptives&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Known or suspected hypersensitivity to trial product or related products&#xD;
&#xD;
          -  Receipt of an investigational drug within 30 days prior to visit 0&#xD;
&#xD;
          -  Simultaneous participation in any other clinical intervention trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Steno Diabetes Center Copenhagen</name>
      <address>
        <city>Gentofte</city>
        <state>Capital Region</state>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Johansen NJ, Dejgaard TF, Lund A, Vilsbøll T, Andersen HU, Knop FK. Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial. BMJ Open. 2018 Jun 27;8(6):e021861. doi: 10.1136/bmjopen-2018-021861.</citation>
    <PMID>29950475</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 2, 2017</study_first_submitted>
  <study_first_submitted_qc>January 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2017</study_first_posted>
  <last_update_submitted>July 9, 2019</last_update_submitted>
  <last_update_submitted_qc>July 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Filip Krag Knop</investigator_full_name>
    <investigator_title>Professor, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type 1</keyword>
  <keyword>Exenatide</keyword>
  <keyword>Incretins</keyword>
  <keyword>GLP-1</keyword>
  <keyword>Insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

